Drug Type Small molecule drug |
Synonyms AB103, AB103e, AB103i |
Target |
Action degraders, inhibitors |
Mechanism ZFP91 degraders(Protein cereblon/E3 ubiquitin-protein ligase ZFP91 degraders), α-synuclein inhibitors(Synuclein alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Brain Injuries, Traumatic | Preclinical | United States | 01 Aug 2026 | |
| Multiple System Atrophy | Preclinical | United States | 01 Aug 2026 | |
| Stroke | Preclinical | United States | 01 Aug 2026 | |
| Alzheimer Disease | Preclinical | United States | 15 May 2024 | |
| Parkinson Disease | Preclinical | United States | 15 May 2024 |





